J.P. Morgan Healthcare Conference https://www.bioworld.com/rss en-us Muted and missing M&As: JPM deals absent in 2026 http://www.bioworld.com/articles/727995 Thu, 15 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/727995-muted-and-missing-m-and-as-jpm-deals-absent-in-2026 Dice spelling out D-E-A-L-?, yes, no Panelists talk benefits, challenges of European drug development http://www.bioworld.com/articles/727993 Thu, 15 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/727993-panelists-talk-benefits-challenges-of-european-drug-development EU flag and microscope Enterobiotix seeks new funds to advance microbiome pill in IBS http://www.bioworld.com/articles/727893 Wed, 14 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/727893-enterobiotix-seeks-new-funds-to-advance-microbiome-pill-in-ibs Pill with British pound sign FDA approves Boston Scientific's Farapoint http://www.bioworld.com/articles/727823 Wed, 14 Jan 2026 11:00:00 -0500 https://www.bioworld.com/articles/727823-fda-approves-boston-scientifics-farapoint Boston Scientific Farapoint Boston Scientific Farapoint. Credit: Boston Scientific Corp. Cell/gene therapy sector now sustainable; China competition mounting http://www.bioworld.com/articles/727884 Tue, 13 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/727884-cell-gene-therapy-sector-now-sustainable-china-competition-mounting Illustration of human body surrounded by DNA, cell and drug icons JPM and beyond: Dealmaking forecast for 2026 http://www.bioworld.com/articles/727880 Tue, 13 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/727880-jpm-and-beyond-dealmaking-forecast-for-2026 Illumina Billion Cell Atlas to accelerate AI, drug discovery holland.johnson@clarivate.com http://www.bioworld.com/articles/727810 Tue, 13 Jan 2026 11:00:00 -0500 https://www.bioworld.com/articles/727810-illumina-billion-cell-atlas-to-accelerate-ai-drug-discovery Illumina sign, building Courtesy of Illumina Inc. Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal http://www.bioworld.com/articles/727982 Tue, 13 Jan 2026 00:00:00 -0500 https://www.bioworld.com/articles/727982-abbvie-snags-pd-1-vegf-bispecific-in-potential-5b-remegen-deal Black and white arrows merging on blue background FDA takes flexibility, modernization steps in CGT, Rx development http://www.bioworld.com/articles/727868 Mon, 12 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/727868-fda-takes-flexibility-modernization-steps-in-cgt-rx-development JPM 2026: Year kicks off with biopharma Q4 revenue and guidance http://www.bioworld.com/articles/727865 Mon, 12 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/727865-jpm-2026-year-kicks-off-with-biopharma-q4-revenue-and-guidance Businesswoman pressing dollar sign on touchscreen Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal http://www.bioworld.com/articles/727866 Mon, 12 Jan 2026 10:00:00 -0500 https://www.bioworld.com/articles/727866-abbvie-snags-pd-1-vegf-bispecific-in-potential-5b-remegen-deal Boston Sci reports good data for Farapulse, Watchman afib systems holland.johnson@clarivate.com http://www.bioworld.com/articles/716016 Fri, 17 Jan 2025 11:00:00 -0500 https://www.bioworld.com/articles/716016-boston-sci-reports-good-data-for-farapulse-watchman-afib-systems FARAPULSE pulsed field ablation system Boston Scientific Corp.’s Farapulse PFA system. Credit: Boston Scientific As wheel Terns in CML, Novartis’ Scemblix in crosshairs http://www.bioworld.com/articles/716351 Thu, 16 Jan 2025 12:00:00 -0500 https://www.bioworld.com/articles/716351-as-wheel-terns-in-cml-novartis-scemblix-in-crosshairs Microscopic image of blood cells, chronic myeloid leukemia and thrombocytosis Them too in TREM2: Street keeping AD Vigil http://www.bioworld.com/articles/716297 Wed, 15 Jan 2025 12:00:00 -0500 https://www.bioworld.com/articles/716297-them-too-in-trem2-street-keeping-ad-vigil TREM2 structure Detailed TREM2 structure. Credit: Daniel L Kober, Washington University School of Medicine in St. Louis JPM: CBER’s Marks ‘reassured’ as FDA to refine warnings on CAR Ts http://www.bioworld.com/articles/716296 Wed, 15 Jan 2025 12:00:00 -0500 https://www.bioworld.com/articles/716296-jpm-cbers-marks-reassured-as-fda-to-refine-warnings-on-car-ts Biotech Showcase: GLP-1s and the search beyond obesity http://www.bioworld.com/articles/716294 Wed, 15 Jan 2025 12:00:00 -0500 https://www.bioworld.com/articles/716294-biotech-showcase-glp-1s-and-the-search-beyond-obesity Targets with arrows Natera reports on robust product pipeline at JPM holland.johnson@clarivate.com http://www.bioworld.com/articles/715991 Wed, 15 Jan 2025 11:00:00 -0500 https://www.bioworld.com/articles/715991-natera-reports-on-robust-product-pipeline-at-jpm Purple-tinted test tubes and dropper Abbvie and Simcere enter a $1B T-cell engager deal http://www.bioworld.com/articles/716338 Tue, 14 Jan 2025 12:00:00 -0500 https://www.bioworld.com/articles/716338-abbvie-and-simcere-enter-a-1b-t-cell-engager-deal Illustration of cell receptors, antibodies Alliance for Regenerative Medicine: Field growing, cost still an issue http://www.bioworld.com/articles/716257 Tue, 14 Jan 2025 12:00:00 -0500 https://www.bioworld.com/articles/716257-alliance-for-regenerative-medicine-field-growing-cost-still-an-issue DNA in drug capsules JPM: Sling’s small molecule has success in thyroid eye disease http://www.bioworld.com/articles/716256 Tue, 14 Jan 2025 12:00:00 -0500 https://www.bioworld.com/articles/716256-jpm-slings-small-molecule-has-success-in-thyroid-eye-disease Eye with digital overlay Abbvie and Simcere enter a $1B T-cell engager deal http://www.bioworld.com/articles/716226 Mon, 13 Jan 2025 12:00:00 -0500 https://www.bioworld.com/articles/716226-abbvie-and-simcere-enter-a-1b-t-cell-engager-deal Illustration of cell receptors, antibodies Lilly’s ‘timely’ $2.5B Scorpion deal; GSK pays $1B up front for Idrx http://www.bioworld.com/articles/716225 Mon, 13 Jan 2025 12:00:00 -0500 https://www.bioworld.com/articles/716225-lillys-timely-25b-scorpion-deal-gsk-pays-1b-up-front-for-idrx Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal http://www.bioworld.com/articles/716224 Mon, 13 Jan 2025 12:00:00 -0500 https://www.bioworld.com/articles/716224-caplyta-star-shines-as-j-and-j-takes-intra-cellular-in-146b-deal Collage of businesspeople JPM: Industry cutbacks ‘probably healthy overall’ as (better?) new year begins http://www.bioworld.com/articles/704838 Fri, 19 Jan 2024 12:00:00 -0500 https://www.bioworld.com/articles/704838-jpm-industry-cutbacks-probably-healthy-overall-as-better-new-year-begins Following JPM, 2024 outlook ranges from hopeful to cautious http://www.bioworld.com/articles/704817 Fri, 19 Jan 2024 12:00:00 -0500 https://www.bioworld.com/articles/704817-following-jpm-2024-outlook-ranges-from-hopeful-to-cautious Hand holding 2024 with up arrows Asia CDMO giants Wuxi and Samsung to grow production, ADC capacity http://www.bioworld.com/articles/704652 Tue, 16 Jan 2024 12:00:00 -0500 https://www.bioworld.com/articles/704652-asia-cdmo-giants-wuxi-and-samsung-to-grow-production-adc-capacity Richard Lee, CEO, Lotte Biologics, at JPM24 Lotte Biologics CEO Richard Lee speaks at the 2024 annual J.P. Morgan Healthcare Conference in San Francisco. PCV pipe(lines) robust; Merck at JPM with GSK, Vaxcyte in play http://www.bioworld.com/articles/704640 Fri, 12 Jan 2024 12:00:00 -0500 https://www.bioworld.com/articles/704640-pcv-pipelines-robust-merck-at-jpm-with-gsk-vaxcyte-in-play JPM recap: Biopharma rising to postmarketing challenges in 2024 BioWorld offers a brief glimpse at a few firms taking on those post-approval challenges in 2024.]]> http://www.bioworld.com/articles/704639 Fri, 12 Jan 2024 12:00:00 -0500 https://www.bioworld.com/articles/704639-jpm-recap-biopharma-rising-to-postmarketing-challenges-in-2024 The year of gene therapy? FDA’s Marks calls for solutions to regulatory, manufacturing challenges http://www.bioworld.com/articles/704472 Fri, 12 Jan 2024 07:00:00 -0500 https://www.bioworld.com/articles/704472-the-year-of-gene-therapy-fdas-marks-calls-for-solutions-to-regulatory-manufacturing-challenges DNA in drug capsules New boss in FOS? Xenon featured at JPM; Biohaven also in play http://www.bioworld.com/articles/704541 Thu, 11 Jan 2024 12:00:00 -0500 https://www.bioworld.com/articles/704541-new-boss-in-fos-xenon-featured-at-jpm-biohaven-also-in-play